Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints investors, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
Nektar Therapeutics (NKTR) PT Raised to $45 at BTIG Following SITC Meeting
November 13, 2017 8:55 AM ESTBTIG raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $45.00 (from $35.00) while maintaining a Buy rating. At the Society for Immunotherapy of Cancer meeting (SITC), presentation of oral abstract O20 for NKTR-214, Nektars IL-2-based immune stimulator, was very well received.
NKTR-214 +... More
